cell engineering

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
Liora Schultz, Shabnum Patel, Kara Lynn Davis, Sneha Ramakrishna, Bita Sahaf, Neehar Bhatia, Christina Baggott, Courtney Erickson, Robbie G Majzner, Jean Oak, Alice Bertaina, Crystal Mackall, Steven Feldman

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e001073; DOI: 10.1136/jitc-2020-001073
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
Samanta Romina Zanetti, Paola Alejandra Romecin, Meritxell Vinyoles, Manel Juan, José Luis Fuster, Mireia Cámos, Sergi Querol, Mario Delgado, Pablo Menendez

Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e001419; DOI: 10.1136/jitc-2020-001419
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
Talia Velasco-Hernandez, Samanta Romina Zanetti, Heleia Roca-Ho, Francisco Gutierrez-Aguera, Paolo Petazzi, Diego Sánchez-Martínez, Oscar Molina, Matteo Libero Baroni, Jose Luis Fuster, Paola Ballerini, Clara Bueno, Narcis Fernandez-Fuentes, Pablo Engel, Pablo Menendez

Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e000896; DOI: 10.1136/jitc-2020-000896
Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
Yuichi Iida, Rintaro Yoshikawa, Akihiko Murata, Hitoshi Kotani, Yasuhiro Kazuki, Mitsuo Oshimura, Yumi Matsuzaki, Mamoru Harada

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000582; DOI: 10.1136/jitc-2020-000582
Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy
Ping Zhang, Devika Ganesamoorthy, Son Hoang Nguyen, Raymond Au, Lachlan J Coin, Siok-Keen Tey

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000299; DOI: 10.1136/jitc-2019-000299
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni, Diego Sanchez Martinez, Francisco Gutierrez Aguera, Heleia Roca Ho, Maria Castella, Samanta Romina Zanetti, Talia Velasco Hernandez, Rafael Diaz de la Guardia, Julio Castaño, Eduardo Anguita, Susana Vives, Josep Nomdedeu, Helene Lapillone, Anne E Bras, Vincent H J van der Velden, Jordi Junca, Pedro Marin, Alex Bataller, Jordi Esteve, Binje Vick, Irmela Jeremias, Angel Lopez, Marc Sorigue, Clara Bueno, Pablo Menendez

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000845; DOI: 10.1136/jitc-2020-000845
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
Orit Itzhaki, Elad Jacoby, Abraham Nissani, Michal Levi, Arnon Nagler, Adva Kubi, Karin Brezinger, Hadar Brayer, Li-at Zeltzer, Meir Rozenbaum, Helly Vernitsky, Gal Markel, Amos Toren, Abraham Avigdor, Jacob Schachter, Michal J Besser

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000148; DOI: 10.1136/jitc-2019-000148
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
Lucine Marotte, Sylvain Simon, Virginie Vignard, Emilie Dupre, Malika Gantier, Jonathan Cruard, Jean-Baptiste Alberge, Melanie Hussong, Cecile Deleine, Jean-Marie Heslan, Jonathan Shaffer, Tiffany Beauvais, Joelle Gaschet, Emmanuel Scotet, Delphine Fradin, Anne Jarry, Tuan Nguyen, Nathalie Labarriere

Journal for ImmunoTherapy of Cancer Jan 2020, 8 (1) e000311; DOI: 10.1136/jitc-2019-000311

Log in using your username and password

Main menu

Log in using your username and password

You are here

cell engineering